-
公开(公告)号：US5891434A
公开(公告)日：1999-04-06
申请号：US409338
申请日：1995-03-23
申请人： Peter H. Krammer , Klaus-Michael Debatin , Bernhard C. Trauth , Iris Behrmann , Jens Dhein , Christiane Klas , Peter Moller , Werner Falk , Alexander Oehm , Peter T. Daniel
发明人： Peter H. Krammer , Klaus-Michael Debatin , Bernhard C. Trauth , Iris Behrmann , Jens Dhein , Christiane Klas , Peter Moller , Werner Falk , Alexander Oehm , Peter T. Daniel
IPC分类号： A61K38/00 , A61P37/02 , C07K14/705 , C07K16/28 , C12P21/04 , A61K39/395 , A61K39/00 , C07K16/00
CPC分类号： C07K16/2878 , C07K14/70578 , A61K38/00 , C07K2317/73
摘要： The APO-1 cellular membrane antigen, an about 50 kDa antigen associated with cellular apoptosis, and purified cDNA encoding same is described. The antigen is expressed by numerous normal and malignant cells, including activated and malignant lymphoid cells. Also disclosed are antibodies which bind the antigen, and which induce growth inhibition and apoptosis.
摘要翻译： 描述了与细胞凋亡相关的约50kDa抗原的APO-1细胞膜抗原和编码相同的纯化的cDNA。 抗原由许多正常和恶性细胞表达，包括活化和恶性淋巴细胞。 还公开了结合抗原并且诱导生长抑制和细胞凋亡的抗体。
-
2.发明授权Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer 有权罗格列酰与凋亡诱导物质联合用于治疗癌症公开(公告)号：US09387192B2
公开(公告)日：2016-07-12
申请号：US13130019
申请日：2009-11-20
申请人： Min Li-Weber , Peter H. Krammer
发明人： Min Li-Weber , Peter H. Krammer
IPC分类号： A61K31/343 , A61K39/395 , A61K45/06
CPC分类号： A61K31/343 , A61K31/513 , A61K31/704 , A61K31/7068 , A61K38/177 , A61K38/1774 , A61K38/191 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2875 , C07K16/2878 , C07K2317/73 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
摘要翻译： 本发明涉及包含至少一种罗格列酰胺衍生物和至少一种凋亡诱导剂的组合制剂，优选来自包含诱导外源性凋亡途径的试剂的物质组，抗增殖剂和通过活化诱导诱导T细胞凋亡的试剂 细胞死亡（AICD）用于治疗癌症。
-
3.发明申请COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER 有权联合治疗癌症的药代动力学和药物诱导物质的组合公开(公告)号：US20110250166A1
公开(公告)日：2011-10-13
申请号：US13130019
申请日：2009-11-20
申请人： Min Li-Weber , Peter H. Krammer
发明人： Min Li-Weber , Peter H. Krammer
IPC分类号： A61K38/19 , A61P35/00 , A61K39/395 , A61K31/343 , A61K31/36
CPC分类号： A61K31/343 , A61K31/513 , A61K31/704 , A61K31/7068 , A61K38/177 , A61K38/1774 , A61K38/191 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2875 , C07K16/2878 , C07K2317/73 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
摘要翻译： 本发明涉及包含至少一种罗格列酰胺衍生物和至少一种凋亡诱导剂的组合制剂，优选来自包含诱导外源性凋亡途径的试剂的物质组，抗增殖剂和通过活化诱导诱导T细胞凋亡的试剂 细胞死亡（AICD）用于治疗癌症。
-
4.发明申请COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER 审中-公开联合治疗癌症的药代动力学和药物诱导物质的组合公开(公告)号：US20160374983A1
公开(公告)日：2016-12-29
申请号：US15196973
申请日：2016-06-29
申请人： Min LI-WEBER , Peter H. Krammer
发明人： Min LI-WEBER , Peter H. Krammer
IPC分类号： A61K31/343 , A61K39/395 , A61K38/17 , A61K38/19
CPC分类号： A61K31/343 , A61K31/513 , A61K31/704 , A61K31/7068 , A61K38/177 , A61K38/1774 , A61K38/191 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2875 , C07K16/2878 , C07K2317/73 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
摘要翻译： 本发明涉及包含至少一种罗格列酰胺衍生物和至少一种凋亡诱导剂的组合制剂，优选来自包含诱导外源性凋亡途径的试剂的物质组，抗增殖剂和通过活化诱导诱导T细胞凋亡的试剂 细胞死亡（AICD）用于治疗癌症。
-
5.发明授权Methods and compounds for treating diseases caused by reactive oxygen species 失效用于治疗由活性氧引起的疾病的方法和化合物公开(公告)号：US08563500B2
公开(公告)日：2013-10-22
申请号：US12676617
申请日：2007-09-05
CPC分类号： A61K31/7088 , A61K31/155
摘要： Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the complex I-mediated ROS production, a medicament containing such compound and methods for screening for such compounds.
摘要翻译： 提供了通过使用抑制复合物I介导的ROS产生的化合物治疗患有炎性疾病的患者的方法，含有这种化合物的药物和用于筛选这些化合物的方法。
-
6.发明申请METHODS AND COMPOUNDS FOR TREATING DISEASES CAUSED BY REACTIVE OXYGEN SPECIES 失效用于治疗由反应性氧物质引起的疾病的方法和化合物公开(公告)号：US20100305187A1
公开(公告)日：2010-12-02
申请号：US12676617
申请日：2007-09-05
IPC分类号： A61K31/713 , A61K31/155 , A61P37/06 , A61P25/16 , A61P19/02 , C12Q1/02 , C07C279/26
CPC分类号： A61K31/7088 , A61K31/155
摘要： Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the complex I-mediated ROS production, a medicament containing such compound and methods for screening for such compounds.
摘要翻译： 提供了通过使用抑制复合物I介导的ROS产生的化合物治疗患有炎性疾病的患者的方法，含有这种化合物的药物和用于筛选这些化合物的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
